Actionable insights straight to your inbox

Equities logo

GlaxoSmithKline Enters Into License Agreement with Sosei for Inflammatory Bowel Disease Treatments

Sosei will receive upfront payment, potential near-term development milestones and research funding of up to £34 million (US$46 million) and could receive additional milestone payments of up to £336 million (US$454 million).